Los Angeles Allergist

Los Angeles Allergist

Alan Khadavi, MD, APC
  • Home
  • Meet Dr. Khadavi
  • Conditions We Treat
  • Your First Visit
  • Insurance Accepted
  • Allergy and Asthma Info
    • Asthma Info
    • Allergic Rhinitis
    • Allergic Triggers
  • Blog
  • Media
  • Contact Us

9001 Wilshire Blvd. Suite 204
Beverly Hills, CA 90211
Phone: 310-282-8822

16260 Ventura Blvd., Suite 140
Encino, CA 91436
Phone: 818-528-7776

September 25, 2021 by Alan Khadavi

Opzelura (ruxolitinib) for Eczema

Opzelura (ruxolitinib) has been FDA approved for eczema. Opzelura is a topical JAK inhibitor, and its indicated for short term use in patients 12 and up who have mild to moderate atopic dermatitis. It is the first topical janus kinase inhibitor approved in the United States.

Currently for atopic dermatitis topical treatment, the mainstay of treatment are topical corticosteroids, such as hydrocortisone, triamcinolone and there are many to choose from. Elidel/Protopic were the next topical treatments approved, followed by Eucrisa. Opzelura is the first topical therapy in its class to be approved for eczema.

We have discussed extensively in the past JAK inhibitors for atopic dermatitis, but most of them are being studied in the oral form.

Abrocitinib for Atopic Dermatitis by Pfizer

Upadacitinib for Atopic Dermatitis (Eczema)

JAK inhibitors block an inflammatory pathway that lead to different immune responses. JAK inhibitors are currently used inflammatory diseases such as rheumatoid arthritis and treatments of cancer.

The approval of Ruxolitinib was based on 2 phase 3 studies involving more than 1200 patients with mild to moderate eczema. Approximately 52% of patients receiving Ruxolitinib reached the primary endpoint of treatment goals after 8 weeks.

The most common adverse events were nasopharyngitis, diarrhea, bronchitis and ear infections. Although more adverse events can be reported once the medication is used in a broader population.

With other oral JAK inhibitors on the way, it remains to be seen which treatment would be better in the topical vs. the oral route of these medications.

Most new medications like Opzelura are significantly expensive when they are first released on the market. But the manufacturer, in this case Incyte Dermatology, provides coupons or discounts to patients when the drug is not covered by insurance companies.

Stay tuned for more information, Ruxolitinib cream is also being evaluated for the treatment of vitiligo. To read more, please click on the link below regarding a blog that was written about it last year.

Ruxolitinib for Eczema (atopic dermatitis)

Atopic Dermatitis (Eczema) Treatment

Treatment of Atopic Dermatitis (Eczema)

 

 

Filed Under: atopic dermatitis, Blog, Medications

alan-khadavi
Dr. Alan Khadavi
Allergy & Asthma Specialist

Latest Posts

May 24, 2022

Lirentelimab study for Chronic Urticaria (Hives)

lirentelimab

May 24, 2022

Dupixent for EoE (Eosinophilic Esophagitis); FDA approved and New Dosing

dupixent for eoe

April 30, 2022

What are the best foods for Asthma?

best foods for asthma

April 26, 2022

Best Nasal Polyps Treatment

best nasal polyps treatment

April 19, 2022

Fasenra for Nasal Polyps, a new treatment option

fasenra for nasal polyps

April 19, 2022

Asivatrep a new topical treatment for Eczema

asivatrep cream

April 3, 2022

Kiwi Allergy can come in many flavors

Kiwi allergy

March 15, 2022

Ana o 3 IgE in diagnosing Cashew Nut Allergy

Ana o 3

March 13, 2022

Does Expired Albuterol work?

expired albuterol

March 8, 2022

Itepekimab in Asthma and COPD

itepekimab for asthma

Read More Posts...

Follow Us…

© 2022 Allergy Los Angeles. All Rights Reserved · Log in · Return to top of page